SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients

Author(s)

Trarbach, Ericka B. ; Jorge, Alexander A. ; Duarte, Felipe H. ; Bronstein, Marcello D. ; Jallad, Raquel S.

• Document type: Journal article
• Source: Pituitary; v. 20, n. 3, p. 319-324, JUN 2017.
• Web of Science Citations: 0

Abstract

Purpose Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly. Methods Four SOCS2 SNPs (rs3782415, rs3816997, rs3825199 and rs11107116) were selected and genotyped by real-time PCR using specific Taqman probe assays. A total of 186 patients (116 women, age range 26-88 years) were evaluated. Results No association of SOCS2 genotypes was observed with none of the following clinical and laboratorial characteristics: age, sex, body mass index, comorbidities, basal GH, oral glucose tolerance test GH nadir, IGF-I, ULNRIGF-I. Conclusion Despite of the key role of SOCS2 in the regulation of GH receptor signaling, we did not find any significant association between SOCS2 polymorphisms and acromegaly. (AU)

• FAPESP's process: 10/11718-1 - Polymorphisms in genes of GH receptor (GHR) and IGFBP3 in acromegaly: correlation with clinical / laboratory parameters and response to therapy
• Grantee: Marcello Delano Bronstein
• Support Opportunities: Regular Research Grants